Nuvalent (NUVL) Common Equity (2020 - 2026)
Nuvalent (NUVL) posted Common Equity of $1.2 billion for Q1 2026, down 5.93% on a QoQ basis from $1.2 billion in Q4 2025, and up 16.15% year-over-year from $1.0 billion in Q1 2025.
Nuvalent (NUVL) Common Equity (2020 - 2026) Analysis & Trends
Nuvalent's Common Equity history runs 7 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- Quarterly Common Equity rose 16.15% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 16.15% YoY) and the FY2025 annual result came in at $1.2 billion, up 16.69% from the prior year.
- Common Equity was $1.2 billion for Q1 2026 at Nuvalent, down from $1.2 billion in the prior quarter.
- Across five years, Common Equity topped out at $1.2 billion in Q4 2025 and bottomed at $236.6 million in Q3 2022.
- A 5-year average of $700.3 million and a median of $675.0 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 796.22% — and 2025, when it declined 24.59%.
- Nuvalent's Common Equity stood at $463.0 million in 2022, then jumped by 51.32% to $700.6 million in 2023, then soared by 52.71% to $1.1 billion in 2024, then rose by 16.69% to $1.2 billion in 2025, then fell by 5.93% to $1.2 billion in 2026.
- Business Quant data shows NUVL's Common Equity at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $845.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | 1.25 Bn |
| Sep 30, 2025 | 845.40 Mn |
| Jun 30, 2025 | 939.74 Mn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 1.07 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 637.04 Mn |
| Mar 31, 2024 | 675.04 Mn |
| Dec 31, 2023 | 700.56 Mn |
| Sep 30, 2023 | 395.98 Mn |
| Jun 30, 2023 | 421.15 Mn |
| Mar 31, 2023 | 443.97 Mn |
| Dec 31, 2022 | 462.98 Mn |
| Sep 30, 2022 | 236.58 Mn |
| Jun 30, 2022 | 252.99 Mn |
| Mar 31, 2022 | 268.92 Mn |
| Dec 31, 2021 | 285.04 Mn |
| Sep 30, 2021 | 301.13 Mn |
| Jun 30, 2021 | -47.74 Mn |